CN104292123B - The succinamide derivative of phenyl naphthalene nucleus, Preparation Method And The Use - Google Patents
The succinamide derivative of phenyl naphthalene nucleus, Preparation Method And The Use Download PDFInfo
- Publication number
- CN104292123B CN104292123B CN201410501869.4A CN201410501869A CN104292123B CN 104292123 B CN104292123 B CN 104292123B CN 201410501869 A CN201410501869 A CN 201410501869A CN 104292123 B CN104292123 B CN 104292123B
- Authority
- CN
- China
- Prior art keywords
- compound
- present
- preparation
- naphthalene nucleus
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to the pharmaceutical field relevant to hyperuricemia and gout.Specifically, the present invention relates to uric acid transporter body 1 inhibitor of the succinamide structure of a class phenyl naphthalene nucleus, its preparation method and preparing the application in diabetes medicament containing their pharmaceutical composition and they.
<b> (I) </b> wherein, R
1, R
2definition as used in the description.
Description
Technical field
The present invention relates to the pharmaceutical field that treatment hyperuricemia is relevant with gout.Specifically, the present invention relates to hyperuricemia and the medicative class of gout containing uric acid transporter body 1 (uratetransporter1, the URAT1) inhibitor of the succinamide derivative of phenyl naphthalene nucleus, preparation method, containing they pharmaceutical composition and in purposes pharmaceutically.
Background technology
Gout is a kind of chronic metabolic disease, and the pain being deposited on the positions such as joint with hyperuricemia and monosodium urate salt (MSU) and causing is for principal character, and major cause is purine metabolic disturbance and/or uric acid excretion disorder.According to estimates, current global patient with gout has more than 2,000 ten thousand.The medicine being used for the treatment of gout at present comprises for lenitive anti-inflammatory drug (as colchicine etc.), suppresses uricogenesis medicine (xanthine oxidase inhibitor being representative with allopurinol and Febuxostat), thick uric acid excretion medicine (the uric acid excretion medicine being representative with probenecid, sulfinpyrazone, benzbromarone and losartan) and uriKoxidase (with pegloticase for representative).There is the toxic side effect of different degree in these medicines, as benzbromarone has the danger causing explosive hepatitis, allopurinol has liver and the untoward reaction such as bone marrow toxicity and transformation reactions, etc.
Lesinurad (RDEA594) be a kind of developed by Ardea company can suppress uric acid transporter body (uratetransporter1 in kidney, URAT1) discharged the oral pharmaceutical of uric acid in blood by the approach of urine, be in III phase clinical stage at present.The antiviral RDEA806 that Lesinurad is researched and developed by Valeant company the earliest develops.The right of ownership of present Lesinurad is at present because Ardea company is belonged to AstraZeneca by purchasing.
The invention discloses the URAT1 inhibitor of the succinamide derivative of a class phenyl naphthalene nucleus, these compounds can be used for the medicine preparing treatment hyperuricemia and gout.
Summary of the invention
An object of the present invention is to provide one and there is excellent activity, there is general formula
ia compounds.
Another object of the present invention is to provide preparation and has general formula
ithe method of compound.
Another object of the present invention is to provide containing general formula
icompound as effective constituent, and the medicinal compositions of one or more pharmaceutically acceptable carrier, vehicle or thinners, and the application in treatment gout.
Now in conjunction with object of the present invention, content of the present invention is specifically described.
the present invention have general formula I compound and pharmaceutically acceptable prodrug ester there is following structural formula:
(I)
Wherein, R
1be selected from H, halogenic substituent;
R
2be selected from H, C
1-C
5alkyl, C
3-C
6cycloalkyl.
preferably: R
1be selected from F, Cl, Br, I substituting group;
R
2be selected from C
1-C
4alkyl, C
3-C
4cycloalkyl.
further, the compound of preferred formula I has following structure,
。
further, the compound of preferred formula I has following structure,
。
compound of Formula I of the present invention is synthesized by following route:
Compound
iIwith with monomethyl succinate
iIIcondensation under condensing agent exists, obtains compound
iV; Compound
iVhydrolysis obtains compound in the presence of a base
v; Compound
vwith compound R
2nH (
vI) condensation under condensing agent exists, obtain product
i.Described condensing agent is selected from DCC, EDC, TBTU and HATU etc.Described R
1, R
2definition as previously mentioned.
General formula of the present invention
icompound has the restraining effect of URAT1, can be used as the medicine of effective constituent for the preparation of hyperuricemia and gout.General formula of the present invention
ithe activity of compound is verified by receptor binding assays.
General formula of the present invention
icompound is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 1mg-500mg/ people, is divided into once or administration for several times.Actually take general formula of the present invention
ithe dosage of compound can be decided according to relevant situation by doctor.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
embodiment 1
。
A. compound
iV-1synthesis
5.06g (20mmol) compound
iI-1with 2.64g (20mmol) compound
iIIbe dissolved in the THF of 50mL drying, ice-water bath cooling is lower stirs, add dicyclohexyl carbodiimide (DCC) 4.13g (20mmol) and DMAP (DMAP) 0.61g (5mmol), then stirred at ambient temperature, until TLC detection reaction completes (within 12h).Reaction mixture is poured in 300mL frozen water, stirs, and uses the CH of 100mL × 3
2cl
2extraction, merges extraction phase, uses the dilute hydrochloric acid of 100mL1% and the salt water washing of 100mL5% successively, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound
iV-1, white solid, ESI-MS,
m/z=390 ([M+Na]
+).
B. compound
v-1synthesis
Compound
iV-15.50g (15mmol) is dissolved in 30mL anhydrous methanol, stirred at ambient temperature, adds the LiOH solution of 3mL10%, then continues under room temperature to stir, until TLC detection reaction completes (within 5h).
Reaction mixture is poured in 200mL frozen water, stirs, regulates pH=2-3 with concentrated hydrochloric acid.Use the CH of 100mL × 3
2cl
2extraction, merges extraction phase, uses the salt water washing of 100mL5%, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification (short column), obtains compound
v-1, faint yellow solid, ESI-MS,
m/z=352 ([M-H]
-).
C. compound
i-1synthesis
3.53g (10mmol) compound
v-1with 0.73g (10mmol) compound
vI-1be dissolved in the THF of 30mL drying, ice-water bath cooling is lower stirs, add dicyclohexyl carbodiimide (DCC) 2.06g (10mmol) and DMAP (DMAP) 0.61g (5mmol), then stirred at ambient temperature, until TLC detection reaction completes (within 12h).Reaction mixture is poured in 200mL frozen water, stirs, and uses the CH of 70mL × 3
2cl
2extraction, merges extraction phase, uses the dilute hydrochloric acid of 100mL1% and the salt water washing of 100mL5% successively, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound
i-1, white solid.ESI-MS,
m/z=426([M+NH
4]
+)。
embodiment 2-16
With reference to the operation steps of embodiment 1, prepare compound listed in Table.
embodiment 17
The IC that compound of the present invention and related compound suppress URAT1
50be worth the similar method recorded according to document and measure (in US2014/0005136 embodiment 12).Shown in the following list of result.
Build the cell strain of stably express humanization URAT1 transporter: be subcloned into the plasmid pCMV6/neo (Origene) of eukaryotic expression from plasmid pCMV6-XL-5 (Origene) by humanization URAT1 gene (SLC22A112).Gene sequencing confirms humanization URAT1 consistent with the information recorded in gene pool (NM_144585.2).HEK293 human embryonic kidney cell (ATCC#CRL-1573) in EMEM tissue culture medium at the CO of 5%
2cultivate with in the air atmosphere of 95%.L2000 type transfection agents (Invitrogene) is used to be transfected on HEK293 cell by pCMV6/Neo/URAT1.After 24 hours, transfected cell being assigned to diameter is in the tissue culture dishes of 10cm, continued growth one day, then substratum is replaced by the fresh substratum containing 0.5mg/mLG418 (Gibco).After 8 days, select and collect resistance bacterium colony, and right with its test
14the transport activity of the uric acid of C-mark.By HEK293/URAT1 cell with 75, the density in 000/ hole is planted on 96 orifice plates that cover in poly-D-Lys.
These cells grow overnight under 37 ° of C in incubator, then under cool to room temperature, nutrient solution wherein uses the scavenging solution washing in 250 μ L/ holes once (10mMHEPES of 125mM Sunmorl N 60S, pH=7.3).Testing compound or blank be added to containing 40 μMs
14c-marks in the damping fluid of uric acid (54mCi/mmol), described damping fluid contains 125mM Sunmorl N 60S, 4.8mM Potassium Gluconate, 1.2mM potassium primary phosphate, 1.2mM magnesium sulfate, 1.3mM calglucon, 5.6mM glucose, 25mMHEPES, final pH=7.3.96 orifice plates at room temperature cultivate 10 minutes, then respectively clean three times with the above-mentioned scavenging solution in 50 μ L/ holes and 250 μ L/ holes successively.96 orifice plates add Microscint20 type liquid and dodges agent, plank is overnight incubation under 45 ° of C, then reading on TopCountPlateReader, and calculates IC accordingly
50.Shown in the following list of result:
。
Above-mentioned IC
50measurement result show, compound of the present invention all shows good URAT1 inhibitor, can be used for preparing treatment hyperuricemia and the medicine of gout.
Claims (5)
1. there is the compound of general formula I,
Wherein, R
1be selected from H, halogen;
R
2be selected from H, C
1-C
5alkyl, C
3-C
6cycloalkyl.
2. the compound with general formula I that claim 1 defines,
Wherein, R
1be selected from F, Cl, Br, I;
R
2be selected from C
1-C
4alkyl, C
3-C
4cycloalkyl.
3. the compound of Formula I that defines of claim 2, is selected from:
4. the compound of Formula I that defines of claim 3, is selected from further:
5. the compound of Formula I that any one of claim 1-4 defines is preparing the application in treatment hyperuricemia and gout medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410501869.4A CN104292123B (en) | 2014-09-27 | 2014-09-27 | The succinamide derivative of phenyl naphthalene nucleus, Preparation Method And The Use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410501869.4A CN104292123B (en) | 2014-09-27 | 2014-09-27 | The succinamide derivative of phenyl naphthalene nucleus, Preparation Method And The Use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104292123A CN104292123A (en) | 2015-01-21 |
| CN104292123B true CN104292123B (en) | 2015-12-02 |
Family
ID=52312117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410501869.4A Expired - Fee Related CN104292123B (en) | 2014-09-27 | 2014-09-27 | The succinamide derivative of phenyl naphthalene nucleus, Preparation Method And The Use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104292123B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111943957B (en) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | Quinoline formamide compound and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1087625A (en) * | 1992-09-25 | 1994-06-08 | 比奥·梅加·贝林格尔·英格海姆研究公司 | N-(hydroxyethyl) succinic diamide derivative |
| US5344957A (en) * | 1991-10-15 | 1994-09-06 | G.D. Searle & Co. | Substituted β-amino acid derivatives useful as platelet aggregation inhibitors |
| CN103524440A (en) * | 2013-10-15 | 2014-01-22 | 苏州鹏旭医药科技有限公司 | Preparation method of gout curative medicine Lesinurad and midbody of Lesinurad |
-
2014
- 2014-09-27 CN CN201410501869.4A patent/CN104292123B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5344957A (en) * | 1991-10-15 | 1994-09-06 | G.D. Searle & Co. | Substituted β-amino acid derivatives useful as platelet aggregation inhibitors |
| CN1087625A (en) * | 1992-09-25 | 1994-06-08 | 比奥·梅加·贝林格尔·英格海姆研究公司 | N-(hydroxyethyl) succinic diamide derivative |
| CN103524440A (en) * | 2013-10-15 | 2014-01-22 | 苏州鹏旭医药科技有限公司 | Preparation method of gout curative medicine Lesinurad and midbody of Lesinurad |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104292123A (en) | 2015-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104311442B (en) | The succinamide derivative of halo naphthalene nucleus, Preparation Method And The Use | |
| CN104292123B (en) | The succinamide derivative of phenyl naphthalene nucleus, Preparation Method And The Use | |
| CN104262277B (en) | Containing nitro and the tetrazoleacetic acid compounds of halobenzene replacement, Preparation Method And The Use | |
| CN104193644B (en) | The succinamide derivative of methoxy naphthalene nucleus, Preparation Method And The Use | |
| CN104311441B (en) | Succinamide derivative, the Preparation Method And The Use of one class chloro naphthalene nucleus | |
| CN104292124B (en) | Naphthalene nucleus succinamide derivative, Preparation Method And The Use that nitrophenyl replaces | |
| CN104311443B (en) | The naphthalene-ring containing succinamide derivative of one class, Preparation Method And The Use | |
| CN104311452B (en) | The succinamide derivative of itrile group naphthalene nucleus, Preparation Method And The Use | |
| CN104311445B (en) | Naphthalene-ring containing succinamide derivative, Preparation Method And The Use | |
| CN104292178B (en) | Containing tetrazoleacetic acid compounds, Preparation Method And The Use | |
| CN104262276B (en) | Tetrazoleacetic acid compounds containing halogeno-benzene, Preparation Method And The Use | |
| CN104311444B (en) | Nitro replaces succinamide derivative, the Preparation Method And The Use of naphthalene nucleus | |
| CN104341364A (en) | Triazole malonic acid compounds as well as preparation method and application thereof | |
| CN104370841A (en) | Triazolesulfinylmalonic acid compounds as well as preparation method and application thereof | |
| CN104311498B (en) | Triazole sulphonyl propanedioic acid compounds, Preparation Method And The Use that alkoxyl group replaces | |
| CN104341362A (en) | Triazolesulfonylmalonic acid compounds as well as preparation method and application thereof | |
| CN104230833B (en) | The tetrazoleacetic acid compounds of nitrile group-containing, Preparation Method And The Use | |
| CN104326999B (en) | Alkoxy-substituted triazole sulfinyl malonate type compound, and preparation method and application thereof | |
| CN104326998B (en) | Phenyl substituted triazole malonic acid compounds, Preparation Method And The Use | |
| CN104292177B (en) | Nitrile group-containing and halobenzene substituted tetrazoleacetic acid compounds, Preparation Method And The Use | |
| CN104370842B (en) | The triazole sulphonyl malonic acid compounds of phenyl replacement, Preparation Method And The Use | |
| CN104326997B (en) | Alkoxyl substituted triazole malonic acid compounds, Preparation Method And The Use | |
| CN104292175B (en) | Tetrazoleacetic acid compounds containing nitro, Preparation Method And The Use | |
| CN104370843A (en) | Halotriazolesulfinylmalonic acid compounds as well as preparation method and application thereof | |
| CN104341365A (en) | Halogenated triazole malonic acid compounds as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Cui Lingling Inventor before: The inventor has waived the right to be mentioned |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170906 Address after: 476800, Henan province civil rights county dragon town, Tao Zheng Village Patentee after: Cui Lingling Address before: 528000 Guangdong, Foshan District, Pu Lan Road, the first floor of the first floor, No. 5, Chancheng Patentee before: Zhang Yuanqiang |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151202 Termination date: 20180927 |